The gastric modifier esomeprazole did not affect the bioavailability and tolerability of CS-7017 in an open-label, phase I, two-way crossover clinical study in healthy subjects

被引：0
|
作者：
Scheyer, R. [1 ]
Zahir, H. [1 ]
Luo, R. [1 ]
He, L. [1 ]
Noveck, R. [2 ]
Liu, K. [3 ]
机构：
[1] Daiichi Sankyo Pharma Dev, Translat Med, Edison, NJ USA
[2] MDS Pharma Serv, DMPK & Drug Safety Assessment, New York, NY USA
[3] Daiichi Sankyo Pharma Dev, Biostat, Edison, NJ USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72023-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：101 / 101
页数：1
相关论文
共 50 条
  • [1] Co-administration of a CYP3A4 inhibitor (ketoconazole) increased the bioavailability of CS-7017 but did not affect tolerability: results from an open-label, phase I, two-way crossover study in healthy subjects
    Senaldi, G.
    Zahir, H.
    He, L.
    Rasmussen, J. C.
    Liu, K.
    Scheyer, R.
    EJC SUPPLEMENTS, 2010, 8 (07): : 104 - 105
  • [2] Food does not affect the pharmacokinetics of CS-7017 in healthy subjects: results from an open label, phase I, two-treatment, three-period, crossover study
    Scheyer, R.
    Zahir, H.
    Luo, R.
    He, L.
    Noveck, R.
    Liu, K.
    EJC SUPPLEMENTS, 2010, 8 (07): : 104 - 104
  • [3] Ambroxol lozenge bioavailability - An open-label, two-way crossover study of the comparative bioavailability of ambroxol lozenges and commercial tablets in healthy Thai volunteers
    Rojpibulstit, M
    Kasiwong, S
    Juthong, S
    Phadoongsombat, N
    Faroongsarng, D
    CLINICAL DRUG INVESTIGATION, 2003, 23 (04) : 273 - 280
  • [4] Relative Bioavailability and Pharmacokinetic Properties of Two Different Enteric Formulations of Esomeprazole in Healthy Bangladeshi Male Volunteers: An Open-Label, Single-Dose, Randomized-Sequence, Two-Way Crossover Study
    Ullah, Md. Ashik
    Shams-Ud-Dowla
    Al Maruf, Abdullah
    Azad, Mohammad Abul Kalam
    Shohag, Md. Hasanuzzaman
    Sultana, Rebeka
    Latif, A. H. M. Mahbub
    Hasnat, Abul
    CLINICAL THERAPEUTICS, 2010, 32 (07) : 1419 - 1426
  • [5] Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers:: A single-dose, randomized, open-label, two-way crossover study
    Solans, Anna
    Carbo, Marcel-li
    Pena, Juana
    Nadal, Teresa
    Izquierdo, Inaki
    Merlos, Manuel
    CLINICAL THERAPEUTICS, 2007, 29 (05) : 900 - 908
  • [6] Ambroxol Lozenge BioavailabilityAn Open-Label, Two-Way Crossover Study of the Comparative Bioavailability of Ambroxol Lozenges and Commercial Tablets in Healthy Thai Volunteers
    Malee Rojpibulstit
    Srirat Kasiwong
    Siwasak Juthong
    Narubodee Phadoongsombat
    Damrongsak Faroongsarng
    Clinical Drug Investigation, 2003, 23 : 273 - 280
  • [7] A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension
    Li, Yan
    Liu, Liangang
    Huang, Lian
    Wang, Xiaomin
    Hoffmann, Matthew
    Reyes, Josephine
    Palmisano, Maria
    Zhou, Simon
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2018, 10 : 1089 - 1099
  • [8] Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects A single, randomized, two-way cross-over, open-label phase I study
    Izquierdo, Inaki
    Borja, Javier
    Rovira, Sandra
    Pelagio, Pilar
    Torres, Ferran
    Cebrecos, Jesus
    Garcia-Rafanell, Julian
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2010, 60 (01): : 36 - 41
  • [9] A PHASE I, SINGLE-DOSE, RANDOMIZED, OPEN-LABEL, CROSSOVER, RELATIVE BIOAVAILABILITY, AND FOOD EFFECT STUDY OF BELVARAFENIB IN HEALTHY SUBJECTS.
    Malhi, V.
    Monemi, S.
    Dolton, M.
    Kapp, A.
    Angelaud, R.
    Zhang, W.
    Eng-Wong, J.
    Sullivan, C.
    Mueller, L.
    Musib, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S43 - S43
  • [10] A Phase I, Open-label, Randomized, 2-Way Crossover Study to Evaluate the Relative Bioavailability of Intranasal and Oral Varenicline
    Nau, Jeffrey
    Wyatt, David J.
    Rollema, Hans
    Crean, Christopher S.
    CLINICAL THERAPEUTICS, 2021, 43 (09) : 1595 - 1607
12345